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The International Collaborative Effusion (ICE) database: A European Respiratory Society Clinical 
Research Collaboration. 
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Main text 
Background 
Pleural medicine is now well-established as an important subspecialty of respiratory medicine, with 
pleural effusions alone estimated to affect over 2 million people per year in Europe. [1] The range of 
pleural conditions is broad, encompassing those which are malignant or benign; treatable and 
requiring palliation; and both acute or chronic. Interventions such as thoracoscopy and indwelling 
pleural catheters play a key role in the pleural specialist’s arsenal, as does the increasingly 
ubiquitous thoracic ultrasound. Indeed, technological improvements have not only fuelled the 
ultrasound revolution but have also led to developments in other forms of diagnostic imaging and 
testing specifically geared towards the patient with a pleural condition. [2] 
To coincide with the above, over the last decade there has been a surge in the number of major 
studies, many of them randomised controlled trials, focusing on conditions such as malignant pleural 
effusion, mesothelioma, and pleural infection. [3-8] The results of these have had an immediate and 
practice changing effect on an international scale, even going so far as to change how entire 
treatment options are offered to patients in some centres, [4] demonstrating an ongoing hunger for 
the highest quality evidence base amongst respiratory physicians with an interest in pleural disease. 
This wave of robustly-designed, sufficiently-powered studies and trials will hopefully continue over 
the coming years. 
There are, however, significant challenges to delivering clinically-orientated research in those with 
pleural disease. Conditions such as pleural infection and pneumothorax tend to be identified and 
require treatment in the acute setting, minimising the opportunity for study involvement. 
Additionally, those with malignant pleural disease are often highly comorbid and/or in need of 
palliative measures, once again restricting the ability to enrol sufficient numbers into trials; recent 
data have shown that, in some cases, despite large numbers of patients being screened, the number 
who actually progress to randomisation or treatment allocation can be surprisingly low. [3] Finally, in 
comparison to other conditions which sit under the wider respiratory umbrella (such as pulmonary 
hypertension), research into pleural disease is relatively underfunded, a fact in no small part down 
to a lack of true understanding of pleural pathophysiology and thus the possibility of novel 
pharmacological treatment targets.  
In many cases, the key to overcoming some of these hurdles is wider collaboration, broadening the 
pool of potential participants to compensate for any individual site’s local challenges to obtaining 
data. This ethos is particularly vital when one accepts that, in addition to those detailed above, there 
are a range of important pleural conditions which are rarer or harder to classify, with the 
management and knowledge of many of these conditions founded upon single-centre case series 
only. They nonetheless remain clinically relevant to many general respiratory practitioners, for 
example due to a tendency to require recurrent intervention or because there exists a theoretical 
risk of progression to a more significant or malignant condition. [9] 
 
A Pleural Clinical Research Collaboration 
Recognising the limitations of single-centre work, there is a strong desire to contribute to larger-
scale projects amongst pleural-interested physicians.[10, 11] In an attempt to leverage this, the 
Thoracic Oncology Assembly of the European Respiratory Society have supported the creation of the 
International Collaborative Effusion (ICE) database as part of the Clinical Research Collaboration 
(CRC) scheme. [12]  
The aims of the ICE database are to establish consistent, effective working amongst pleural 
practitioners on a scale never-before attempted, leading to wider participation in important pleural 
research and, potentially, to lay the groundwork for more ambitious, multinational projects. The 
intended focus of the database is primarily on those conditions which are ‘under-represented’ in the 
pleural literature, with a view to creating a foundation upon which practice-changing studies in 
these areas may be designed. 
 
The ICE database to date 
The collaboration was inaugurated in 2017, with co-ordination and hosting provided by the 
Academic Respiratory Unit in Bristol, UK, who have a strong background in delivering multicentre 
pleural studies of various designs. Initial membership was drawn from the ERS Pleural Interest 
Group, who meet on at least a yearly basis at the annual Congress. At the time of writing there are 
16 sites spread across 11 European countries, as well as South Africa, who have agreed to participate 
in the initial stages of the project, although the potential exists for this number to increase 
dramatically if the early stages of the project are felt to be successful. We would encourage those 
who may wish to contribute to the CRC to make contact with the corresponding author. 
From the outset, the ICE Collaboration has placed the democratic process and group collaboration at 
the centre of its work, taking the view that having greater input and ‘ownership’ of a project for all 
sites, small and large, will lead to both better engagement with data entry and with any future 
undertakings. As a first step in this, discussions were had as to the general format of the data which 
would be collected. It was decided that focusing on a series of simultaneous, large-scale 
retrospective studies would be the most effective starting point for the Collaboration, but doing so 
in a way which created a platform for future prospective data collection projects. Data would be 
entered by each site directly onto a centralised research database, which would be designed in such 
a way that expansion to additional projects or revisiting established ones would be possible. 
Following this, all members of the CRC were asked to provide a list of up to three topics which they 
felt to be important and worthy of further study. A total of 17 topics were suggested, spanning the 
breadth of pleural conditions and challenges, before being voted on by the whole group to 
determine which the ICE database would focus on. The four most voted-for disease areas were: 
Chylothorax, eosinophilic effusions, non-specific pleuritis, and recurrent non-malignant effusions 
caused by organ failure (e.g. hepatic hydrothorax). Examination of the literature demonstrates that 
these topics, as well as being of clear clinical interest, are in need of more robust data to support 
practice. The largest series relating to non-malignant pleural effusions (not limited to those related 
to organ failure) contained 356 patients over 7 years. [13] For chylothorax, the equivalent is another 
study) which described the outcomes of 203 patients over 21 years. [14] Eosinophilic effusions and 
non-specific pleuritis have been addressed in studies with only 135 and 208 patients respectively. 
[15, 16] Almost all series, including those listed here, are limited by drawing data from single-
centres.   
The next stage was to identify and agree research questions, along with the more specific data 
points which sites would be asked to provide for each condition (see table 1). Priority was given to 
finding a balance between collecting robust data sets without overburdening those busy clinicians 
who would be tasked with finding and entering the information. By whole-group agreement, small 
(2-3 person) ‘topic subgroups’ were formed, with each of these leading on identifying relevant 
research questions as well as suggesting specific data points to be gathered (see table 1). Once each 
subgroup had completed this, there ensued two rounds of comment, review and adjustment by the 
wider team, before the final datasets were confirmed. At the time of writing, the trial database is in 
the later stages of being built and tested, using the product of the efforts of the whole pleural CRC as 
a template. 
 
Table 1 – Initial ICE database subtopics and associated research questions 
CRC subtopic Selected Important Research Questions 
Chylothorax • What are the common presenting features of chylothorax? 
• What are the commonest causes of chylothorax? 
• How is chylothorax typically/best investigated? 
• What treatments are typically required/used for chylothorax? 
• What are the negative outcomes associated with 
chylothorax? 
Eosinophilic pleural 
effusions (EPE) 
• What is the incidence of EPE? 
• Is there an association between EPE and systemic 
eosinophilic diseases. 
• What is the prevalence of malignanant pleural effusion in 
patients with EPE? 
• What are the most effective diagnostic procedures in EPE? 
• What proportion of EPE are related to earlier pleural 
diseases/interventions (e.g. spontaneous pneumothorax, an 
earlier diagnostic thoracentesis)? 
• What is the prevalence and what agents are associated with 
drug-induced eosinophilic pleural effusion? 
Non-specific pleuritis 
(NSP) 
• What are the commonest causes of NSP? 
• How many patients with an initial diagnosis of NSP develop 
malignancy during subsequent follow up?  
• Is development of malignancy (false-negative NSP) related to 
thoracoscopic technique or difficulty? 
• What is the minimal safe follow-up time of NSP to exclude 
malignancy as eventual diagnosis?  
• What percentage was probably infective in nature, and what 
were the causes if identified? 
Non-malignant effusions 
(NME) secondary to 
cardiac, renal or hepatic 
dysfunction  
• What are the baseline characteristics of patients who develop 
NME?  
• What are the prognostic features of NME?  
• What are the features of refractory NME?  
• What treatments (medical and interventional) are typically 
required for NME? 
• What are the complications with pleural intervention in 
patients with NME?  
 
Moving forward 
Once finalised, the ICE database will be used to generate what we anticipate being the largest series 
ever published for each of the four topics in question. Data entry is expected to begin in the Summer 
of 2019. Analysis will be led by each of the small topic groups, with each manuscript being made 
available for review by each CRC member, cementing the collegiate nature of this project. Our hope 
is that this early work can act as proof that the concept of sustained, large, multinational 
collaborations in pleural conditions can be both feasible and successful. 
The longer-term ambition for the ICE database goes further, with it potentially being used to rapidly 
generate future cohorts for other low-incidence pleural conditions. Additionally, if the challenges of 
negotiating local ethics applications can be overcome, we will also be able to undertake even more 
robust, prospective projects, all using the same platform. In fact, we believe that the ICE database 
and pleural CRC may become the underpinnings of a large-scale (potentially industry-supported) 
biobank, with such an entity potentially able to offer the greater insights into the pathophysiology of 
pleural disease that is desperately needed to drive the next generations of pleural research 
questions and improvements in patient care. 
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